Calling all media inquiries! Pay attention to our recent findings and give us a call to talk to the expert directly. Contact Liz Moore to schedule some time to get insightful, unbiased, fact-based answers to your questions.
Avalere experts say that the impact for most hospitals will be modest.
Katherine Steinberg comes to Avalere Health with more than 15 years’ experience in the healthcare arena.
Prescription drugs are not outsized contributors to rate increases.
The plans are waiting to see how frameworks will evolve and if physicians embrace them before relying on them to decide which prescription drugs to cover.
Data show gaps in care integration across provider settings following hospital discharges.
Rates vary widely by state; popular low cost options see smaller increases.
Wendy Everett, ScD, joins Avalere as a senior advisor.
Earlier today, the Centers for Medicare and Medicaid Services (CMS) released participation information for its new Oncology Care Model (OCM) slated to begin July 1.
Hepatitis C and Oncology Are Top Therapeutic Area Targets
Cost-sharing changes could increase costs for many beneficiaries.
Avalere and Inovalon recently entered into an agreement with Bristol-Meyers Squibb (BMS) to support the manufacturer's innovative initiatives using real-world outcomes data to design and test value-based contracting models. The agreement brings together Avalere's deep expertise on manufacturer and payer contract negotiation and Inovalon's significant data assets to meet the complex challenges around ensuring value and access while addressing growing healthcare costs concerns.
A new Avalere analysis finds that nearly 13 million Americans age 50 or over who are currently uninsured or have individual coverage purchased through the private market-inside and outside the exchange- could be eligible to buy-in to the Medicare program under a plan proposed by Democratic presidential candidate Hillary Clinton.
Christie Teigland, PhD, vice president, Advanced Analytics, recently received the Academy of Managed Care Pharmacy’s (AMCP) prestigious Platinum Award for her research entitled “Association of Socioeconomic and Clinical Factors with Rates of High-Risk Medication Use in Medicare Advantage Plans.”
Two Potential Policy Changes Would Reduce Out-of-Pocket Costs for Consumers
Rule Would Decrease Medicare Reimbursement for Drugs That Cost More than $480 per Day; Seven of the 10 Most Affected Drugs Treat Cancer
One third of those who enrolled in a health insurance plan on Healthcare.gov this year picked the same plan as last year, according to a new analysis from Avalere. In total, 3.2 million of the 9.6 million exchange shoppers in 2016 kept their previous plan.
Hospitals should focus on care after discharge, which drives more than 39 percent of spending.
Percentage of drugs in Part D plans that require coinsurance increased significantly since 2014. Medicare Advantage plans require coinsurance far less often than Part D plans.
Avalere and Inovalon have entered into a multi-year agreement with Kindred Healthcare, Inc., the nation’s largest provider of post-acute care (PAC) services, to deploy the power of data and analytics to engage payers. The combined solutions will result in a data-driven platform that will support Kindred in improving clinical outcomes and promoting coordinated, efficient care under new value-based payment models.
A new analysis by Avalere finds that, despite efforts by policymakers to encourage broader vaccination rates, Medicare enrollees have limited access to a set of 10 recommended vaccines without having to pay out-of-pocket (e.g., co-payments).